The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity
Key facts
- Where
- Amsterdam and Nieuwegein, NetherlandsSee the 2 sites
Where in Netherlands
- NOK clinicsAmsterdam, NetherlandsTaking people
- NOK clinicsNieuwegein, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Radboud University Medical Center
- Trial code
- NCT07929831
- Record updated
- 10 November 2026
- Original description
The goal of this observational study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity.Read full original descriptionShow less
Uncovering the Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity: an Observational Prospective Cohort
The goal of this observational study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity.
The main questions this study aims to answer are:
* What is the composition of weight loss during incretin treatment? * What is the composition of recurrent weight gain after stopping incretin treatment?
An additional question this study aims to answer is:
- How do muscle strength and physical function change during and after incretin treatment?
Two groups of patients will be included: patients who start with incretin therapy for overweight/obesity and patients who stop incretin therapy for overweight/obesity.
Participants who start incretin treatment will have measurements before starting treatment, after six months, and after twelve months or when treatment is stopped. Participants who stop incretin treatment will have measurements before stopping treatment, after six months, and after twelve months or before restarting treatment.
Measurements include:
* Height, length, waist circumference * Body composition measured with InBody, with a Dual-Energy X-ray Absorptiometry in a subgroup of the participants * Muscle strength tests * Physical function tests * Blood samples to asses metabolic health * Physical activity measured with an activity monitor (ActivPAL) * Questionnaires about health, incretin treatment, physical activity, and diet
No treatment or medication will be given as part of the study. Participants will receive incretin treatment as part of their usual care.
Inclusion: Screened and planned to start with incretin treatment or currently using incretin and planned to discontinue treatment; Aged 18 years or older.
Exclusion: Prior use of incretins, or other obesity medication; Inability to comprehend scheduled procedures (e.g., language barriers); Unable to perform the physical tests due to physical disabilities; Patients who underwent MBS or including endoscopic interventions and gastric balloon placement.